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Abstract
Introduction: Increased expression of IL-33 and its receptor ST2, encoded by the IL1RL1 gene, has been detected in the
inflamed arteries of giant cell arteritis (GCA) patients. The aim of the present study was to investigate for the first time the
potential influence of the IL33 and IL1RL1 loci on GCA predisposition.
Methods: A total of 1,363 biopsy-proven GCA patients and 3,908 healthy controls from four European cohorts (Spain, Italy,
Germany and Norway) were combined in a meta-analysis. Six genetic variants: rs3939286, rs7025417 and rs7044343, within
the IL33 gene, and rs2058660, rs2310173 and rs13015714, within the IL1RL1 gene, previously associated with immune-
related diseases, were genotyped using predesigned TaqMan assays.
Results: A consistent association between the rs7025417 polymorphism and GCA was evident in the overall meta-analysis,
under both allele (PMH = 0.041, OR = 0.88, CI 95% 0.78–0.99) and recessive (PMH = 3.40E-03, OR = 0.53, CI 95% 0.35–0.80)
models. No statistically significant differences between allele or genotype frequencies for the other IL33 and IL1RL1 genetic
variants were detected in this pooled analysis.
Conclusions: Our results clearly evidenced the implication of the IL33 rs7025417 polymorphism in the genetic network
underlying GCA.
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Introduction
Giant cell arteritis (GCA) is a chronic granulomatous vasculitis
of large and medium size blood vessels which affects predomi-
nantly women and people generally older than 50 years [1].
Although the mechanisms triggering this pathology remain
unclear, both immune and genetic factors appear to participate in
its pathogenesis. The inflammatory process occurring in GCA is
mainly driven by Th1 and Th17 lymphocytes and macrophages
[2]. Additionally, endothelial cells also play an important role in
the induction and perpetuation of the inflammation by promoting
neoangiogenesis [3]. Regarding the genetic component of this
vasculitis, besides HLA, a few risk factors have been consistently
associated with GCA so far [4,5] and, therefore, most of the
genetic contribution to this disorder continues unidentified.
IL-33 has recently been described as a novel IL-1 family
member with strong immunomodulatory functions. This cytokine,
through binding to its receptor ST2 (suppression of tumorigenicity
2), encoded by the interleukin 1 receptor-like 1 (IL1RL1) gene,
activates mast cells and Th2 lymphocytes, leading to the
production of chemokines, pro-inflammatory and Th2-associated
cytokines, and increased serum immunoglobulin levels [6].
Additionally, it has been shown that IL-33 acts as an activator
of endothelial cells promoting angiogenesis and vascular perme-
ability in vitro and in vivo [7].
Different studies have supported a pathogenic role of IL-33 axis
in autoimmunity [8,9,10,11]. Regarding genetic studies, several
polymorphisms within the IL33 region have been associated with
different immune-related conditions. Specifically, rs3939286 was
associated with asthma [12], nasal polyposis [13] and inflamma-
tory bowel disease (IBD) [14], rs7025417 was associated with
coronary artery disease (CAD) [15], and rs7044343 with
rheumatoid arthritis [16]. In addition, three other IL33 polymor-
phisms, in high linkage disequilibrium (LD) with rs3939286
(rs928413, rs2381416 and rs1342326), have been related to
asthma through genome-wide association studies (GWASs)
[17,18,19]. On the other hand, a number of IL1RL1 polymor-
phisms have also been implicated in autoimmunity. In this line, the
rs2058660, rs2310173 and rs13015714 genetic variants were
associated with Crohn’s disease [20], ulcerative colitis and
ankylosing spondylits [21,22], and, celiac disease and inflamma-
tory bowel disease [14,23], respectively. Moreover, an association
between three tightly linked polymorphisms (rs10197862,
rs13408661 and rs3771180) and asthma has also been described
in GWASs [18,24,25].
Interestingly, an increased expression of IL-33 and ST2 has
been detected in the inflamed arteries of GCA patients, mainly in
endothelial cells of newly formed vessels, thus suggesting a possible
role of IL-33 in the angiogenesis-dependent inflammation in GCA
[26].
The aim of the present study was to assess whether genetic
variants at IL33 and IL1RL1, previously associated with immune-
mediated diseases, are involved in the genetic predisposition to this
vasculitis.
Methods
Study population
The case-control study included a total of 1,363 biopsy-proven
GCA patients and 3,908 unrelated healthy controls, both of
European ancestry. First, a discovery cohort, consisting of 894
Spanish GCA cases and 2,047 controls was analyzed. Subse-
quently, a replication phase was conducted in three independent
cohorts from Germany (103 cases and 444 controls), Italy (255
cases and 1,141 controls) and Norway (111 cases and 276
controls). Table S1 summarizes the main characteristics of the
analyzed cohorts. Case/control sets were matched by geographical
origin and ethnicity. Informed written consent from all partici-
pants and approval from the local ethical committees (Comite´ de
Bioe´tica del Consejo Superior de Investigaciones Cientı´ficas,
Comitato di Etica e Sperimentazione Farmaci Fondazione IRCCS
Ca’ Granda-Ospedale Maggiore Policlinico di Milano, Ethic
Committee Provinciale of Reggio Emilia, Local Ethics Commit-
tees of the Hospital Vall d’Hebron, Hospital Clinic, Hospital de la
Princesa, Hospital Clı´nico San Carlos, Hospital Universitario de
Bellvitge, Hospital Universitario Marque´s de Valdecilla, Oslo
University Hospital, Hospital of Southern Norway Trust, Robert-
Bosch-Hospital, University of Luebeck, Hannover Medical
School, Universita` degli Studi di Verona, University of Genova
and University Hospital of Parma) were obtained in accordance
with the tenets of the Declaration of Helsinki. All patients had a
positive temporal artery biopsy (disruption of the internal elastic
laminae with infiltration of mononuclear cells into the arterial wall
with or without multinucleated giant cells) and fulfilled the 1990
American College of Rheumatology classification criteria [27].
Patients were stratified according to the presence or absence of
polymyalgia rheumatica (PMR), visual ischaemic manifestations
(VIM; if they experienced transient visual loss including amaurosis
fugax, permanent visual loss, or diplopia) and irreversible occlusive
disease (IOD; if they had at least one of the following features:
permanent visual loss, stroke or occlusive disease in the upper
extremities or lower extremities).
Genotyping methods
The selection of single-nucleotide polymorphisms (SNPs) was
based on their position and previous association with several
inflammatory conditions. Polymorphisms with minor allele
frequencies lower than 10% were not included as power
calculations indicated a lack of statistical power to analyze them.
Following these criteria, six polymorphisms, three in the IL33
region (rs3939286, rs7025417 and rs7044343), located in different
haplotype blocks of this locus, and three in the IL1RL1 region
(rs2058660, rs2310173 and rs13015714), were genotyped using
the TaqMan allelic discrimination assay technology on a 7900HT
Fast Real-Time PCR System, both from Applied Biosystems
(Foster City, California, USA).
Statistical analysis
Table S2 shows the overall statistical power of the analysis
(http://www.sph.umich.edu/csg/abecasis/CaTS/). Plink (v1.07)
(http://pngu.mgh.harvard.edu/purcell/plink/) and StatsDirect
v.2.6.6 (StatsDirect Ltd, Cheshire, UK) were used to perform
262 contingency tables and x2 test. Odds ratios (OR) and 95%
confidence intervals (CI) were obtained according to Woolf’s
method. P-values of the discovery cohort were corrected by The
Benjamini & Hochberg (1995) step-up false discovery rate (FDR)
control correction for multiple testing [28]. P-values ,0.05 were
considered statistically significant. The analysis of the combined
data from all populations was performed using Plink and
StatsDirect. Breslow–Day (BD) test and Cochran’s Q and I2
statistics were used to estimate the homogeneity among popula-
tions. Pooled analyses were performed by Mantel-Haenszel (MH)
test under fixed effects.
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Results
Genotypic frequencies did not deviate from those predicted by
Hardy-Weinberg (P.0.01) and the genotype success rate were .
95%.
Table 1 shows the genotype and allelic frequencies of the IL33
and IL1RL1 polymorphisms analyzed in the Spanish discovery
cohort. In the allele test, none of the studied polymorphisms
showed a significant association with GCA, although a trend of
association was evident for the IL33 rs7025417 SNP (P = 0.082,
OR = 0.87 [0.75–1.02]). When the recessive model was consid-
ered, the frequency of the minor genotype of IL33 rs7025417 was
significantly reduced in patients compared to healthy controls
(P = 7.04E-03, OR = 0.46 [0.26–0.81]), even after applying FDR
correction (PFDR = 0.042). No significant differences were found
between patients with and without specific clinical features, i.e.
PMR, VIM and IOD, (data not shown). Regarding IL1RL1, none
of the analyzed genetic variants showed association with GCA in
the case/control (Table 1) or subphenotype analysis (data not
shown).
To further examine these findings, the three IL33 genetic
variants were analyzed in three independent case/control sets
Figure 1. Forest plots showing the odds ratios (OR) and confidence intervals (CI) of the IL33 rs2075417 genetic variant under allelic
(A) and recessive (B) genetic models in the discovery and replication cohorts.
doi:10.1371/journal.pone.0113476.g001
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from Germany, Italy and Norway (Table 2). In the Italian set, a
clear association between the rs3939286 polymorphism and GCA
was found (P = 2.37E-03, OR = 0.70 [0.55–0.88]). No association
between IL33 genetic variants and GCA was evident in the
German and Norwegian sets. Subsequently, since no heterogene-
ity between the ORs from the four cohorts was evident (PBD.0.1;
Cochran’s Q-statistic p.0.1; I2 = 0% for rs7025417 and
rs7044343; I2 = 16% for rs3939286), they were combined in a
meta-analysis. As shown in Table 2, only the rs7025417
polymorphism showed a consistent association with GCA in both
allele (P = 0.041, OR = 0.88 [0.78–0.99], Figure 1A) and reces-
sive model (P = 3.40E-03, OR = 0.53 [0.35–0.80], Figure 1B).
The subphenotype analysis according to the main clinical features
of GCA yielded negative results in the pooled analysis (data not
shown).
Discussion
In the present study, we identified for the first time an
association between the IL33 gene and GCA through a large
meta-analysis of four European cohorts. The minor allele (C) and
genotype (CC) of the rs7025417 genetic variant showed a
protective effect, consistently with that described in a previous
study performed in CAD patients [15]. Interestingly, this
polymorphism seems to produce an altered regulation of the
IL33 gene expression [15]. In addition, the rs7025417 risk allele
(T) correlates with an increase of the IL-33 plasma level in CAD
[15]. Our findings would suggest that the rs7025417 genetic
variant might influence the development of GCA by regulating the
expression of IL-33 [26].
Although the combined analysis of the four cohorts evidenced
that only one of the three IL33 tested polymorphisms, rs7025417,
was associated with GCA (probably due to the larger sample size
of the Spanish set), another different SNP, rs3939286, showed a
clear association in the Italian cohort. Both IL33 genetic variants,
rs7025417 and rs3939286, have been previously associated with
autoimmune diseases [12,13,14,15] and they appear to be
regulatory DNA elements according to the public database
RegulomeDB [29], but with minimal evidence of being located
in a functional region (scores 5 and 6, for rs7025417 and
rs3939286, respectively). As for rs7025417, the minor allele of the
rs3939286 conferred protection to GCA, which is the opposite
effect to that previously reported in asthma, nasal polyposis and
IBD [12,13,14]. This could be indicating a different molecular
effect of this SNP in the pathogenesis of GCA than in other
autoimmune diseases. In addition, both SNPs are located in
different haplotype blocks and present a low LD (D9= 0.13 and
r2 = 0.01), which suggests that they may represent independent
signals. Nevertheless, the fact that different IL33 polymorphisms
were associated with GCA in different populations may indicate
that none of them is the real causal variant of the association but
genetic markers in linkage disequilibrium with it. Small changes in
the LD pattern between populations might result in different SNPs
being the most associated with the disease in different cohorts.
In spite of an increased expression of the ST2 receptor was
detected in the inflamed arteries of GCA patients [26], none of the
tested IL1RL1 polymorphisms showed association with this
vasculitis. Taking into account that the statistical power of our
analysis was high enough to detect a possible weak signal (power .
80% to detect an OR .1.20 in the discovery cohort), our data rule
out an important role of the analyzed IL1RL1 genetic variants in
GCA.
Angiogenesis has been proposed as one of the main mechanisms
influencing the progression of GCA [30]. Interplay between
inflammation and angiogenesis is mainly mediated by cytokines,
chemokines, and growth factors, which also induce increase
vascular permeability. In recent years, genetic studies have
supported this crucial role of angiogenesis in GCA. In this line,
variations within the vascular endothelial growth factor (VEGF)
gene, encoding the best known angiogenic factor, have been
associated with this vasculitis [4]. Like VEGF, IL-33 also exerts its
angiogenic and vasopermeability activities in a nitric oxide (NO)-
dependent manner [7]. Interestingly, a role for two genes encoding
NO synthases (NOS2A, cytokine-inducible, and NOS3, endothe-
lial) has also been demonstrated in GCA [4].
In conclusion, our results clearly indicate a role of the IL33
rs7025417 polymorphism as a novel genetic risk factor contrib-
uting to the GCA susceptibility. The effect of additional and
unexplored IL33 and IL1RL1 genetic variants in GCA suscep-
tibility cannot be discarded.
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